| Identification | Back Directory | [Name]
STACHYOSE | [CAS]
54261-98-2 | [Synonyms]
LUPEOSE
STACHYOSE
Water-sugar
MANNOTETRAOSE
STACHYOSE N-HYDRATE
StachyoseHydrate>
STACHYOSE USP/EP/BP
Stachyose hydrate(1:x)
Stachyose hydrate,98.5%
Stachyose hydrate, 97+%
Water su sugar Probiotics
Stachyose hydrate froM Stachys tuberifera 98%
beta-D-Fructofuranosyl O-alpha-D-Galactopyranosyl-(1-6)-O-alpha-D-galactopyranosyl-(1-6)-alpha-D-glucopyranoside
Lupeose
Manneotetrose
Lupeose, α-D-Gal-(1-6)-α-D-Gal-(1-6)-α-D-Glc-(1-2)-β-D-Fru, β-D-Fructofuranosyl-O-α-D-galactopyranosyl-(1-6)-O-α-D-galactopyranosyl-(1-6)-α-D-glucopyranoside | [EINECS(EC#)]
207-427-3 | [Molecular Formula]
C24H42O21 | [MDL Number]
MFCD00006631 | [MOL File]
54261-98-2.mol | [Molecular Weight]
666.58 |
| Chemical Properties | Back Directory | [Melting point ]
110 °C(dec.) | [storage temp. ]
-20°C | [solubility ]
DMSO: 1 mg/ml,PBS (pH 7.2): 10 mg/ml | [Water Solubility ]
Soluble in water | [form ]
Liquid | [color ]
Clear colorless to yellow to pale brown, may darken during storage | [biological source]
plant (Stachys tuberifera) | [Optical Rotation]
[α]24/D +133°, c = 4 in H2O | [BRN ]
5710666 | [Stability:]
Hygroscopic | [InChIKey]
YDBMRUQRXAFOAH-KTDNCYJLSA-N | [SMILES]
O.OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@H]3O[C@H](O[C@]4(CO)O[C@H](CO)[C@@H](O)[C@@H]4O)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O |
| Hazard Information | Back Directory | [Uses]
Stachyose Hydrate is a low molecular weight carbohydrate that was separated through an EM Gel OR-PVA column. | [Biological Activity]
Stachyose belongs to the raffinose family of oligosaccharides (RFOs) | [in vivo]
Stachyose hydrate (200, 400, 600 mg/kg, p.o., once daily for 3 weeks) alleviates colitis symptoms, restores intestinal barrier integrity, and modulates pro-inflammatory and anti-inflammatory cytokine expression in DSS (HY-116282C)-induced ulcerative colitis C57BL/6J mice[2]. | Animal Model: | DSS (HY-116282C)-induced ulcerative colitis C57BL/6J mouse model[2] | | Dosage: | 200, 400, 600 mg/kg | | Administration: | Oral gavage (p.o.), once daily for 3 weeks | | Result: | Significantly alleviated colitis symptoms in DSS-induced colitis mice, including reducing weight loss, lowering disease activity index (DAI), and increasing colon length, while restoring colonic epithelial barrier integrity.
Dose-dependently upregulated mRNA expression of ZO-1, Claudin-1, and Occludin, reduced IL-17, TNF-α, IL-1β, and IL-6 expression, and increased IL-10 levels. |
| [IC 50]
Human Endogenous Metabolite |
|
|